View Older Stories

Feb 6, 2026 08:02AM Clearmind Medicine partners with Polyrizon for intranasal MEAI formulation

Feb 6, 2026 07:57AM Polyrizon partners with Clearmind to develop intranasal MEAI formulation

Jan 14, 2026 08:55AM Clearmind Medicine completes treatment for second patient cohort in trial

Dec 24, 2025 09:15AM Clearmind Medicine advances alcohol disorder drug trial, reports safety data

Dec 16, 2025 08:45AM Clearmind Medicine completes second cohort enrollment in AUD trial

Dec 5, 2025 05:01PM Clearmind Medicine receives NASDAQ minimum bid price deficiency notice

Dec 2, 2025 07:57AM Clearmind Medicine doses first patient with CMND-100 at Hadassah Medical Center

Dec 1, 2025 08:57AM Clearmind Medicine receives safety board approval for alcohol disorder trial

Nov 26, 2025 04:18PM Clearmind Medicine (CMND) files for 5.78M share offering by selling stockholders

Nov 25, 2025 07:17AM Clearmind Medicine enrolls first patient at Tel Aviv medical center

Nov 24, 2025 08:51AM Clearmind Medicine receives approval to continue phase I trial

Nov 20, 2025 06:45AM SciSparc files Israeli patent for depression treatment combination therapy

Nov 20, 2025 06:01AM Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 18, 2025 08:57AM Clearmind Medicine reports positive phase I/IIa trial results for AUD treatment

Nov 17, 2025 07:55AM Clearmind Medicine files Israeli patent for depression treatment

Nov 10, 2025 08:07AM Clearmind Medicine completes first cohort in alcohol disorder trial

Nov 5, 2025 06:55AM Clearmind files patent in South Korea for MEAI depression treatment

Oct 31, 2025 07:35AM Clearmind Medicine files U.S. patent application for cocaine addiction therapy

Oct 30, 2025 07:55AM Clearmind Medicine completes first patient cohort in alcohol disorder trial

Oct 27, 2025 09:22AM Clearmind Medicine names Mary-Elizabeth Gifford chief of global impact

Oct 21, 2025 07:25AM Clearmind Medicine completes first cohort enrollment in alcohol disorder trial

Oct 20, 2025 07:42AM SciSparc and Clearmind publish patent application for binge disorders

Sep 19, 2025 04:22PM Clearmind Medicine (CMND) files for 17.02M share offering by selling stockholders

Sep 19, 2025 08:20AM Clearmind Medicine secures $10 million financing agreement

Aug 7, 2025 07:32AM Clearmind Medicine receives patent publication for obesity therapy

Jul 30, 2025 08:21AM Clearmind Medicine files patent for obesity and liver disease therapy

Jul 23, 2025 08:55AM Clearmind Medicine initiates clinical site for alcohol disorder trial

Jul 15, 2025 08:05AM Clearmind adds Johns Hopkins site to alcohol treatment trial

Jul 3, 2025 08:47AM Clearmind Medicine (CMND) Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Jun 30, 2025 09:16AM Clearmind Medicine (CMND) Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Jun 27, 2025 09:00AM Clearmind Medicine (CMND) Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Jun 25, 2025 07:49AM Clearmind Medicine (CMND) Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Jun 23, 2025 07:58AM Clearmind Medicine (CMND) Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Jun 12, 2025 09:25AM Clearmind Medicine (CMND) Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Apr 25, 2025 08:00AM SciSparc (SPRC) -Clearmind (CMND) Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025 07:58AM Clearmind Medicine (CMND) Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 16, 2025 08:40AM Clearmind Medicine (CMND) Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Apr 8, 2025 06:55AM Clearmind Medicine (CMND) Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Apr 1, 2025 08:15AM Clearmind Medicine (CMND) Launches EDC System

Mar 21, 2025 09:28AM Clearmind Medicine's (CMND) Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.

Mar 19, 2025 07:37AM Clearmind Medicine (CMND) to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Mar 18, 2025 07:32AM Clearmind Medicine (CMND) Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Mar 10, 2025 07:27AM Clearmind Medicine (CMND) Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Feb 4, 2025 08:35AM Clearmind Medicine (CMND) Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Jan 6, 2025 08:15AM Clearmind Medicine (CMND) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025 07:50AM SciSparc (SPRC) and Clearmind (CNMD) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Dec 26, 2024 07:02AM Clearmind Medicine (CMND) Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Dec 24, 2024 06:55AM Clearmind Medicine (CMND) Receives IRB Approval for its FDA-Regulated Clinical Trial

Dec 16, 2024 08:46AM Clearmind Medicine (CMND) and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal Format

Oct 10, 2024 08:07AM Clearmind Medicine (CMND) Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100

View Older Stories